Navigation Links
Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:10/1/2010

CAMBRIDGE, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that three abstracts have been accepted for presentation at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, October 29-November 2, 2010 in Boston, Massachusetts). The abstracts being presented are on three of the company's hepatitis C clinical programs: IDX184, IDX320 and IDX375. Full abstracts can now be viewed at the AASLD website at www.aasld.org.

The accepted abstracts are as follows:

  • Lalezari, et al, "A Phase IIa Study of IDX184 in Combination with Pegylated Interferon (PegIFN) and Ribavirin (RBV) in Treatment-Naïve HCV Genotype 1-Infected Subjects" will be featured as an oral presentation on Sunday, October 31st  at 3:45 p.m.

  • Reesink, et al, "Antiviral Activity, Safety and Pharmacokinetics of IDX320, a Novel Macrocyclic HCV Protease Inhibitor, in a 3-Day Proof-of-Concept Study in Patients with Chronic Hepatitis C" will be presented in a late-breaking poster session on Monday, November 1st between 8:00 a.m. – 5:30 p.m.

  • Bruijne, et al, "Phase I Study in Healthy Volunteers and Patients with IDX375, a Novel Non-Nucleoside HCV Polymerase Inhibitor" will be presented in a poster session on Tuesday, November 2nd between 7:00 a.m. – 12:00 p.m.

  • About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information a
    '/>"/>

    SOURCE Idenix Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
    2. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
    3. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
    4. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
    5. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
    6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
    7. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
    8. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
    9. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
    10. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
    11. Hanger Orthopedic Group, Inc. Announces Third Quarter 2010 Earnings Release Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
    (Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
    (Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
    Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
    ... NoviPet , a leading global provider of ... supplements for dogs at the Backer,s 24th Annual Pet Industry ... 2012, in Atlantic City, New Jersey. The new dietary ... City Convention Center. NoviPet intends to widen its offerings in the ...
    ... Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" ... Distribution Specialists, LLC ("HDS") are pleased to announce that ... ("Agreement") with a major pro sports team based in ... of Clotamin.  The Agreement is part of new marketing ...
    Cached Medicine Technology:NoviPet to Present New Food Supplements for Dogs at Pet Industry Spring Trade Show 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 3
    (Date:7/14/2014)... The Encino cosmetic dentist ... Lumineers and porcelain veneers. These restorations are an ... preparation and greater loss of healthy tooth tissue. They ... visible flaws on the tooth. Encino dentist Dr. Mastour ... to ensure they offer the most appropriate treatment recommendations ...
    (Date:7/14/2014)... 14, 2014 (HealthDay News) -- Being physically active in ... Alzheimer,s disease and other types of dementia, suggest the ... we found that physical exercise at various levels, especially ... Geda from the Mayo Clinic, said in an Alzheimer,s ... they are not yet conclusive. More research is needed ...
    (Date:7/14/2014)... July 14, 2014 ... performance liquid chromatography or UPLC is a ... liquid chromatography that involves the use of ... to separate chromatographic compounds. This highly sensitive ... detection and analysis of chromatography samples. UPLC ...
    (Date:7/14/2014)... Huntington Beach, CA (PRWEB) July 14, 2014 ... of thousands of people undergo plastic surgery to reduce ... hit the market, however, eliminates the need to go ... mouth guard that works the jaw muscles, therefore tightening ... of having two chins. , Jawflex is used for ...
    (Date:7/14/2014)... NJ (PRWEB) July 14, 2014 ... established global leader in enterprise-class cloud management, governance, ... platforms, today announced AvePoint software will be available ... managed cloud specialist. , The hosting ... to offer the following AvePoint solutions to new ...
    Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Staying Active May Help Prevent Dementia 2Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3
    ... Speakers ... Exposition (ACE10), June 20-24, in Chicago, Illinois. , ... Denver (Vocus) February 25, 2010 -- Speakers have been ... June 20-24, in Chicago, Illinois. , ,Denis Hayes will be the highlighted speaker at ...
    ... , ... Examines IT Executive,s Opinions on Outsourcing , ... Westborough, MA (PRWEB) February 25, 2010 -- Advans, a ... that highlight the growing popularity of domestic outsourcing. According to the Advans’ IT Outsourcing ...
    ... ... New Inguinal Hernia Product Range Freedom-I, with an Aim to Improve Surgical Outcomes and Take ... ... focused on bringing innovations to the field of medical devices. For the past four years ...
    ... ... for Sports Medicine (AOSSM), in partnership with Genzyme Biosurgery, is pleased to announce a ... of OA progression. , ... Rosemont, IL (Vocus) February 25, 2010 -- The American Orthopaedic Society for ...
    ... ... feel like they are falling apart at home, psychotherapeutic interventions provide families with a growing ... (PRWEB) ... like they are falling apart at home, psychotherapeutic interventions provide families with a growing array ...
    ... ... continue to await their orders of Xyngular Xyng™ as Zija,s NEW! ... Xyngular™ to market months before their NEW! Xyng™ product was released ... People from all over the world are calling to become distributors ...
    Cached Medicine News:Health News:AWWA Announces ACE10 Speakers 2Health News:Advans Survey Reveals that 75 Percent of Executives Prefer Domestic Outsourcing vs. Offshore 2Health News:Insightra Medical Inc Gains CE Mark on the Freedom(TM) Inguinal Hernia Product Range 2Health News:Insightra Medical Inc Gains CE Mark on the Freedom(TM) Inguinal Hernia Product Range 3Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 3Health News:New Approaches to Teen Therapy Bring Results 2Health News:New Approaches to Teen Therapy Bring Results 3Health News:New Approaches to Teen Therapy Bring Results 4Health News:New Approaches to Teen Therapy Bring Results 5Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 2Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 3
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: